Immortal Person-Time in Studies of Cancer Outcomes
Authors:
- 10 August 2009
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (23) , e55-e56
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving ChemotherapyJournal of Clinical Oncology, 2009
- Exclusion of immortal person‐timePharmacoepidemiology and Drug Safety, 2008
- Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome VariablesJournal of Clinical Oncology, 2008
- Impact of CYP2D6*10 on recurrence‐free survival in breast cancer patients receiving adjuvant tamoxifen therapyCancer Science, 2008
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- Clinical Implications of CYP2D6 Genotypes Predictive of Tamoxifen Pharmacokinetics in Metastatic Breast CancerJournal of Clinical Oncology, 2007
- Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysisThe Lancet, 2002
- Left-truncated Data With Age as Time Scale: An Alternative for Survival Analysis in the Elderly PopulationThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 1998
- Statistical Models for Prevalent Cohort Data1993